Evidence map›Paper›PMID 26297384›Full record

ArticleThe Journal of pharmacology and experimental therapeutics2015

Functional selectivity of kappa opioid receptor agonists in peripheral sensory neurons.

Raehannah J Jamshidi, Blaine A Jacobs, Laura C Sullivan, Teresa A Chavera, Rachel M Saylor, Thomas E Prisinzano, William P Clarke, Kelly A Berg

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of pharmacology and experimental therapeutics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Strategies for DevelopingThe Journal of pharmacology and experimental therapeutics · 2020
    Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Making Sense of Pharmacology: Inverse Agonism and Functional Selectivity.The international journal of neuropsychopharmacology · 2018
    Review
  16. Article
  17. Allosterism withinMolecular pharmacology · 2018
    Article
  18. Article
  19. Designing Safer Analgesics via μ-Opioid Receptor Pathways.Trends in pharmacological sciences · 2017
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Raehannah J JamshidiDepartment of Pharmacology (R.J.J., B.A.J., L.C.S., T.A.C., W.P.C., K.A.B.), University of Texas Health Science Center, San Antonio, Texas; and Department of Medicinal Chemistry (R.M.S., T.E.P.), University of Kansas School of Pharmacy, Lawrence, Kansas.
Blaine A JacobsDepartment of Pharmacology (R.J.J., B.A.J., L.C.S., T.A.C., W.P.C., K.A.B.), University of Texas Health Science Center, San Antonio, Texas; and Department of Medicinal Chemistry (R.M.S., T.E.P.), University of Kansas School of Pharmacy, Lawrence, Kansas.
Laura C SullivanDepartment of Pharmacology (R.J.J., B.A.J., L.C.S., T.A.C., W.P.C., K.A.B.), University of Texas Health Science Center, San Antonio, Texas; and Department of Medicinal Chemistry (R.M.S., T.E.P.), University of Kansas School of Pharmacy, Lawrence, Kansas.
Teresa A ChaveraDepartment of Pharmacology (R.J.J., B.A.J., L.C.S., T.A.C., W.P.C., K.A.B.), University of Texas Health Science Center, San Antonio, Texas; and Department of Medicinal Chemistry (R.M.S., T.E.P.), University of Kansas School of Pharmacy, Lawrence, Kansas.
Rachel M SaylorDepartment of Pharmacology (R.J.J., B.A.J., L.C.S., T.A.C., W.P.C., K.A.B.), University of Texas Health Science Center, San Antonio, Texas; and Department of Medicinal Chemistry (R.M.S., T.E.P.), University of Kansas School of Pharmacy, Lawrence, Kansas.
Thomas E PrisinzanoDepartment of Pharmacology (R.J.J., B.A.J., L.C.S., T.A.C., W.P.C., K.A.B.), University of Texas Health Science Center, San Antonio, Texas; and Department of Medicinal Chemistry (R.M.S., T.E.P.), University of Kansas School of Pharmacy, Lawrence, Kansas.
William P ClarkeDepartment of Pharmacology (R.J.J., B.A.J., L.C.S., T.A.C., W.P.C., K.A.B.), University of Texas Health Science Center, San Antonio, Texas; and Department of Medicinal Chemistry (R.M.S., T.E.P.), University of Kansas School of Pharmacy, Lawrence, Kansas.
Kelly A BergDepartment of Pharmacology (R.J.J., B.A.J., L.C.S., T.A.C., W.P.C., K.A.B.), University of Texas Health Science Center, San Antonio, Texas; and Department of Medicinal Chemistry (R.M.S., T.E.P.), University of Kansas School of Pharmacy, Lawrence, Kansas berg@uthscsa.edu.
University of Kansas · USThe University of Texas Health Science Center at San Antonio · US

Funding

Institute for Integration of Medicine & Science: A Partnership to Improve HealthUL1TR001120 · NCATS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI CLARK, ROBERT A, HARGREAVES, KENNETH M · 2013 to 2017
$16.5M
Institutional Research Training GrantT32DE014318 · NIDCR · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Kenneth M Hargreaves · 2002 to 2026
$12.1M
Investigation of Neoclerodanes as Novel Opioid LigandsR01DA018151 · NIDA · UNIVERSITY OF KENTUCKY · PI PRISINZANO, THOMAS EDWARD · 2005 to 2020
$5.7M
Training in Drug Abuse Research: Behavior and NeurobiologyT32DA031115 · NIDA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI CHARLES P FRANCE · 2011 to 2026
$5.2M
TRAINING GRANT IN DYNAMIC ASPECTS OF CHEMICAL BIOLOGYT32GM008545 · NIGMS · UNIVERSITY OF KANSAS LAWRENCE · PI LAMB, AUDREY L · 1994 to 2019
$4.9M
Regulation of opioid receptor function in trigeminal ganglionR01DA024865 · NIDA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI CLARKE, WILLIAM P · 2009 to 2012
$1.3M
Regulation of Kappa opioid receptor-mediated signaling and peripheral analgesiaR01GM106035 · NIGMS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI CLARKE, WILLIAM P · 2014 to 2017
$1.2M
NCATS NIH HHS UL1 TR001120NIDA NIH HHS R01 DA 018151NIDA NIH HHS R01 DA018151NIDA NIH HHS R01 DA 024865NIDA NIH HHS R01 DA024865NIDA NIH HHS T32 DA 031115NIDA NIH HHS T32 DA031115NIDCR NIH HHS T32 DE014318NIDCR NIH HHS T32DE14318NIGMS NIH HHS R01 GM 106035NIGMS NIH HHS R01 GM106035NIGMS NIH HHS T32 GM008545NIGMS NIH HHS T32GM008545
6 · The paper itself

Abstract

Activation of kappa opioid receptors (KORs) expressed by peripheral sensory neurons that respond to noxious stimuli (nociceptors) can reduce neurotransmission of pain stimuli from the periphery to the central nervous system. We have previously shown that the antinociception dose-response curve for peripherally restricted doses of the KOR agonist (-)-(trans)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]benzeneacetamide (U50488) has an inverted U shape. Here, we found that the downward phase of the U50488 dose-response curve was blocked by an inhibitor of extracellular signal-regulated kinase (ERK) activation U0126. Local administration of the selective KOR agonist salvinorin A (Sal-A), also resulted in an inverted U-shaped curve; however, the downward phase was insensitive to U0126. By contrast, inhibition of c-Jun N-terminal kinase (JNK) partially blocked the downward phase of the dose-response curve to Sal-A, suggesting a role for JNK. In cultures of peripheral sensory neurons, U50488 and Sal-A inhibited adenylyl cyclase activity with similar efficacies; however, their ability to activate ERK and JNK differed. Whereas U50488 activated ERK but not JNK, Sal-A activated JNK but not ERK. Moreover, although both U50488 and Sal-A produced homologous desensitization, desensitization to U50488 was blocked by inhibition of ERK activation, whereas desensitization to Sal-A was blocked by inhibition of JNK. Substitution of an ethoxymethyl ether for the C2 position acetyl group of Sal-A reduced stimulation of JNK, prevented desensitization by ethoxymethyl ether for the C2 position acetyl group of Sal-A, and resulted in a monotonic antinociception dose-response curve. Collectively, these data demonstrate the functional selectivity of KOR ligands for signaling in peripheral sensory neurons, which results in differential effects on behavioral responses in vivo.

Indexed as

3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-IsomerAnimalsButadienesCyclic AMPDinoprostoneDiterpenes, ClerodaneDose-Response Relationship, DrugHot TemperatureHyperalgesiaJNK Mitogen-Activated Protein KinasesMaleMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3NitrilesPrimary Cell CultureRats, Sprague-Dawley3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-IsomerButadienesCyclic AMPDinoprostoneDiterpenes, ClerodaneJNK Mitogen-Activated Protein KinasesMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3NitrilesReceptors, Opioid, kappasalvinorin AU 0126

Identifiers

PMID26297384
PMCPMC4613959
OpenAlexW2371116434

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.